Platelet Sub-study of the TWILIGHT Trial

Coronary Artery Disease Clinical Trial

Official title:

Platelet Sub-study of the TWILIGHT Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04001374
• Other study ID #: GCO 15-0769
• Status: Completed
• Start date: June 28, 2015
• Est. completion date: February 28, 2018

Study information

• Verified date: February 2020
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

TWILIGHT study is a multicenter RCT comparing treatment with ticagrelor alone versus ticagrelor plus aspirin in high-risk patients after PCI. All patients will receive DAPT (ticagrelor plus aspirin) for the initial 3 months post-PCI and then be randomized to either Ticagrelor alone OR Ticagrelor plus Aspirin DAPT.

To investigate the pharmacodynamic effects of the two treatments in this trial, a 'Platelet Sub-study' will be conducted only at the Mount Sinai Medical Center. The sub-study will recruit randomized patients from the TWILIGHT Trial at Mount Sinai and conduct specialized blood tests at randomization and one month thereafter. The aim of the Platelet Sub-study is to compare the antithrombotic effects of Ticagrelor alone versus Ticagrelor plus Aspirin using an ex vivo model of thrombosis (Badimon Chamber).

Description:

The present study will enroll a cohort of randomized patients from the TWILIGHT trial at the Mount Sinai Medical Center. These subjects will undergo blood sampling and measurement of thrombotic indices at the time of randomization and 1-6 months thereafter.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: February 28, 2018
• Est. primary completion date: February 28, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients enrolled in the TWILIGHT trial:

Clinical Inclusion Criteria (must meet at least one):

• Adult patients = 65 years of age

• Troponin (+) acute coronary syndrome

• Female gender

• Established vascular disease defined as previous MI, documented PAD or CAD/PAD revascularization

• Diabetes mellitus treated with medications (oral hypoglycemic, subcutaneous injection of insulin)

• Chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or creatinine clearance (CrCl) < 60 ml/min

Angiographic Inclusion Criteria (must meet at least one):

• Multivessel coronary artery disease

• Target lesion requiring total stent length >30 mm

• Thrombotic target lesion(s)

• Bifurcation lesions with Medina X,1,1 classification requiring at least 2 stents

• Left main (=50%) or proximal LAD (=70%) lesion

• Calcified target lesion(s) requiring atherectomy

Exclusion Criteria:

Patients not eligible to participate in the TWILIGHT trial:

• Under 18 years of age

• Contraindication to aspirin

• Contraindication to ticagrelor

• Planned surgery within 90 days

• Planned coronary revascularization (surgical or percutaneous) within 90 days

• Need for chronic oral anticoagulation

• Prior stroke

• Dialysis-dependent renal failure

• Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease, gastrointestinal pathology with a raised risk for bleeding, malignancies with a raised risk for bleeding)

• Emergent or salvage PCI or STEMI presentation.

• Liver cirrhosis

• Life expectancy < 1 year

• Unable or unwilling to provide informed consent

• Women of child bearing potential (as determined by hospital standard of care)

• Fibrinolytic therapy within 24 hours of index PCI

• Concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer

• Platelet count < 100,000 mm3

• Requiring ongoing treatment with aspirin > 325 mg daily.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Infarction
• Myocardial Infarction

Intervention

Drug:
• Ticagrelor
90mg tablet bid for 12 months
• ASA
enteric coated aspirin 81mg-100mg daily p.o. for 12 months

Locations

Country	Name	City	State
United States	Icahn School of Medicine at Mount Sinai	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Juan Badimon

Country where clinical trial is conducted

United States, 

References & Publications (1)

Baber U, Zafar MU, Dangas G, Escolar G, Angiolillo DJ, Sharma SK, Kini AS, Sartori S, Joyce L, Vogel B, Farhan S, Gurbel P, Gibson CM, Fuster V, Mehran R, Badimon JJ. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. J Am Coll — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Thrombus size (Badimon Chamber)	Thrombus area measured 1-6 months after randomization	1-6 months after randomization
Secondary	Platelet aggregation	Platelet aggregation assessed using Multiplate Analyzer 1-6 months after randomization	1-6 months after randomization